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It is understood that drugs regardless of their order of administration can exhibit drug interactions. 
Established on the fact that treatment of hypertension may last for decades and prolong usage of multiple 
drug regimen may induce substantial pathophysiological changes. Hence, This study was designed to 
evaluate the possible synergistic toxic effects of anti-hypertensive (carvedilol), and anti-inflammatory 
drug (celecoxib) alone and in combinations. Well-established MTT assay, Single Cell Gel Electrophoresis 
(SCGE) and Ames assay were employed to evaluate the toxicity at cellular level. Results from MTT assay 
on Vero cell line revealed that drug combinations have more pronounced anti-proliferative activity with 
combine IC50 value of 13.7:47.8 µg/mL. Likewise, exposure of peripheral blood mononuclear cells with 
drug combinations revealed significant (P<0.05) DNA damage (Class 3) in a dose dependent manner 
at concentrations ≥ 0.78: 2.34 µg/mL. However, carvedilol and celecoxib were non mutagenic against 
either mutant strain (TA 100 and TA 98) and combinations have also shown mild to moderate mutagenic 
potential. Nevertheless, upon addition of metabolic activation enzyme, concentration <12.5:37.5 µg/
plate exhibited significant (P<0.05) mutagenicity against both tester strains. In conclusion, this study 
provides additional genotoxicity and mutagenicity data that could be used in considering options for 
formulating regimens with reduced mutagenic potential.
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INTRODUCTION
Hypertension affects seventy six million people 
in the United States and 1 billion worldwide each 
year and projection depicts that by 2030 prevalence of 
hypertension will increase by 7.2% from estimates (Mills 
et al., 2016). Essential hypertension, or hypertension 
of obscure cause, represents beyond 90% of instances 
of hypertension. It tends to cluster in families and 
represents a collection of genetically based diseases or 
syndromes with several resultant inherited biochemical 
abnormalities (Renna et al., 2013). The resulting 
phenotypes can be modulated by various environmental 
factors, thereby altering the severity of blood pressure 
elevation and the timing of hypertension onset. Numerous 
pathophysiologic factors have been implicated in the 
genesis of essential hypertension, obesity and diabetes 
among the most common ones. Hypertension has been 
considered as a silent killer amongst all other ailments 
due to its diminished signs and symptoms. Consequently, 
if hypertension remains undiagnosed (Blood Pressure 
[BP] failing to be checked previously), known to the 
patient, however, left untreated, and known hypertensive 
patients with low adherence to both antihypertensive 
drugs and lifestyle modification can invariably lead to 
chronic kidney disease (CKD) (Mancia et al., 2009). 
Beta-Blockers are antihypertensive medication and, 
together with diuretics, have been the foundation of studies 
signifying their advantages on cardiovascular morbidity 
and mortality. Carvedilol is a vasodilating non-cardio 
specific third-generation β-blocker, unlike conventional 
beta blockers carvedilol has negative hemodynamic and 
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metabolic effects (Fergus, Connell, Ferdinand, 2015). 
Due to these pleotropic activities carvedilol is becoming a 
preferred therapeutic option among medical practitioners. 
Invariably, uncontrolled hypertension often comes with 
co-morbidities. Musculoskeletal pain, associated with 
the inflammatory diseases has the high prevalence in 
hypertensive patients (Panoulas et al., 2008). Studies 
have shown that vascular inflammation is one of the 
leading cause for the development of hypertension and 
arteriosclerosis (Gerli et al., 2005; Savoia, Schiffrin, 
2006). Henceforth, inflammation and hypertension go 
hand in hand. In this scenario, celecoxib, an over the 
counter non-steroidal anti-inflammatory drug (NSAID) 
with mark anti-inflammatory and analgesic properties, 
has become physician’s drug of choice. It is approved 
for the treatment of rheumatoid arthritis, osteoarthritis, 
and acute pain (van Walsem et al., 2015). The anti-
inflammatory and analgesic properties of celecoxib 
result from inhibition of prostaglandin (PG) synthesis by 
selective inhibition of PG G/H synthase-2 usually stated 
as cyclooxygenase 2 (COX-2) (Tarr, Reuter, 2015). The 
use of carvedilol and celecoxib combination has been very 
common in clinical settings and regardless of their order 
of administration such drugs can exhibit drug interaction. 
Moreover, it is impossible to predict the outcome of these 
interactions of the drugs, based on the individual effect, in 
their combinations. Established on the fact that duration 
of treatment of hypertension may last for decades and 
prolong usage of multiple drug regimens may induce 
significant pathophysiological changes at cellular level. 
The overriding goal of this effort is to provide additional 
genotoxicity and mutagenicity data that could be used in 
considering options for formulating prophylaxis/treatment 
regimens with reduced mutagenic potential and thus 
reduced long-term risk for cancer.
MATERIAL AND METHODS
Shodhana Laboratories Private Limited, Hyderabad 
India, kindly donated analytical grade samples of carvedilol 
and celecoxib. Dulbecco’s modified eagle medium 
(DMEM) (Cat no. 12120014, Caisson Lab, USA); Fetal 
bovine serum (Cat no. S181H-500, Bio-west, USA); MTT 
[3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium 
b r o m i d e ] ( C a t .  n o .  2 9 8 9 3 - 1 ,  S i g m a - A l d r i c h , 
USA);dimethylsulfoxide (DMSO)(Cat. no. 0000179027, 
Paneac QuimicaSAU, Spain); metabolic activation 
system (S9)(Cat. no. 505189D, EBPI environmental Bio-
detection products Inc., Canada); Salmonella typhi TA100 
and TA98 tester stains (Environmental Bio-detection 
Products Incorporation (EBPI), Canada); Histopaque /
Lymphocyte Separating Medium (Cat no: S11230L0560, 
Biowest, France, Roswell Park Memorial Institute 
Medium(RPMI-1640)(Cat no;0214003, Caisson, USA); 
Low melting point agarose (LMPA)(Cat. no. 10011055, 
Fine chemicals HT Company, UK); Normal melting point 
agarose(NMPA)(Cat no. 42083100, Fine chemicals HT 
Company, UK);Triton-X100 (Cat no. 242639, Panreeac, 
Spain); sodium hydroxide (Cat. no. 58641, Batch no. 77620, 
Scharlau, Germany); sodium chloride (Cat. NOCHB3266, 
Riedel-de-Haen, Germany); hydrochloric acid (Cat. no. 
AB61, Batch no. 02110133, Labscan, Ireland); Nutrient 
broth (Cat. No. AM5077, LOT no. 1101, UK); purified 
Ager (Cat. no. 306200012, Duplus, UK); hydrochloric 
acid (HCl) (Batch no. 0240133, Cat. no. AB61, Lab scan, 
Ireland); ethidium bromide (LOT no. 1004DU23819; Cat. 
no. 1239-45-8, Bio basic Inc., Canada); histidine (Cat. 
no. 101937, MP biomedical, France); biotin (Cat. no, 
20284101, Daejung Chem Ltd, Korea); sodium azide (Lot 
no. V11052400, Cat. No. 41900064-1, Bioworld, USA); 
phosphate buffer (Lot no. 2431B77, Cat. no. 41620016-1, 
Bioworld, USA); potasium dihydrogen phosphate (Lot. 
no. PO02570500, Batch no. 11650701), Methanol (Lot 
no. 2839070L, Analar (BDH) UK);Trisbase (Cat. no. 
240202362, Lot. no. 26089, Bioworld, USA) and EDTA 
(Lot. no. 62720, RDH Lab, USA) were provided by the 
department of Pharmacology and Toxicology, University 
of Veterinary and Animal Sciences, Lahore, Pakistan. 
Experimental design
Toxic concentrations tested in this experiment were 
carefully selected keeping all the following parameters 
under consideration; 1) maximum repeatable dose 
(MRD) which provides a preview of the toxicology of 
new and old drug combinations; 2) Toxicokinetic (TK) 
range which gives a formal data of drug action at peak 
plasma concentrations of unknown drugs, and 3) Dose 
incrimination (two fold increase) process to evaluate acute, 
sub-chronic and chronic drug toxicity. Finally relevance 
to effective dose of Carvedilol (ED50=0.04 µg/mL)(Cheng 
et al., 2007) and celecoxib (ED50=1.14 µg/mL) (Ouellet, 
Riendeau, Percival, 2001) and clinical indications 
were also taken under consideration (Buckley, Dorato, 
2009). Hence, selective range of cumulative dilutions of 
carvedilol (200 µg/mL, 150 µg/mL, 100 µg/mL, 50 µg/
mL, 25 µg/mL, 12.5 µg/mL, 6.25 µg/mL, 3.12 µg/mL, 
1.56 µg/mL, 0.78 µg/mL) and celecoxib (600 µg/mL, 
450 µg/mL, 300 µg/mL, 150 µg/mL, 75 µg/mL, 37.5 µg/
mL, 18.75 µg/mL, 9.34 µg/mL, 4.68 µg/mL, 2.34 µg/mL) 
were evaluated, alone and in combinations of increasing 
proportion of both drugs. 
Augmented cytotoxic, mutagenic and genotoxic response triggered by carvedilol and celecoxib combinations
Braz. J. Pharm. Sci. 2018;54(1):e17292 Page 3 / 10
Cytotoxicity assay (MTT assay) 
Treatment of cell line
DMEM supplemented with 20% fetal bovine serum 
was used to cultivate adherent Vero cell lines. Adherent 
cells were treated with each test dilutions individually and 
incubated for 48 h in 5% CO2, 95% air at 37
oC. After 48 h, 
viability of Vero cells was measured by adding 20 µL MTT 
dye solution (50 mg/10 mL) in each well and cells were 
further incubated for 3 h (Ohno, Abe, 1991). Once this 
incubation time was completed, 100 μL of 10% DMSO 
were added to the 96 wells. The numbers of the viable 
cells in each well was proportional to the intensity of the 
absorbance of light, which was then read in an ELISA 
plate reader at 570 nm(Mosmann, 1983). Moreover, cell 
survival percentage values were used to evaluate the IC50 
values of carvedilol, celecoxib and their combinations 
using prism graphpad 5. 
Genotoxicity (comet assay)
Lymphocytes separating media was used for the 
extraction of peripheral mononuclear cells (PMN). 
After incubating the PMNs with drug concentrations, 
group of single cells were transferred on frosted cavity 
slides. These pits were filled with Normal melting ager 
(NMA), 0.6% agar layer on top of a 0.6% agar base layer, 
a third top layer comprising of 0.6% low liquefying 
point agar. Slides were placed in lysis solution (2.5 M 
NaCl, 100 mM EDTA, 10 mM Tris, 1%, 10% DMSO 
and 1% Triton) for 18-24 h and later were submersed 
in electrophoresis buffer (0.3 M NaOH, 1 mM EDTA) 
for 40 min, this allowed the DNA strand to break and 
unwind. Later, the power supply was adjusted at 24 
volts and 300 mA. Slides were electrophoresed for 30 
min. Slides were taken out after 30 minutes and placed 
on a dry surface. These slides were then neutralized and 
stained with ethidium bromide (10 mg/50 mL). DNA 
damage was determined by measuring the DNA comet 
length from the core. Quantitation was carried out on 
a fluorescent image analysis system that compared the 
overall length of intact nuclei versus damaged nuclei with 
a comet tail. The comets were observed under fluorescent 
microscope (BX41, product no. 5M16529 TF, Olympus, 
Japan) and pictures were taken with digital microscope 
camera (DP70, product no. 6B05172, Olympus, Japan) 
and analyzed through Image J software for percentage 
fragmentation. Finally comets are characterize in four 
different classes (Singh et al., 1988).
Class 0 = Undamaged Nuclei 
Class 1 = Tail length ≤ Undamaged Nuclei head diameter
Class 2 = Tail length > Undamaged Nuclei head diameter 
but < 2 X Nuclei head diameter
Class 3 = Tail length > 2 X Undamaged Nuclei head 
diameter.
TABLE I - Cell viability of Vero cell line was measured in term of optical density using MTT assay after treatment with various 
doses of Carvedilol, Celecoxib and their combinations with respective controls for 48 hours. 
Carvedilol Celecoxib Carvedilol: Celecoxib Controls
Conc.a ODb±S.D Conc. OD±S.D Conc. OD±S.D Conc. OD±S.D
0.78 0.89±0.06 2.34 0.86±0.01 0.78:2.34 0.79±0.02 Positive 
Control (Blank 
wells)
0.06±0.08
1.56 0.74±0.05 4.68 0.83±0.02 1.56:4.68 0.77±0.08
3.12 0.69±0.07 9.37 0.77±0.02 3.12:9.37 0.74±0.11
6.25 0.64±0.01 18.75 0.70±0.03 6.25:18.75 0.65±0.01*
12.5 0.59±0.01 37.5 0.67±0.02 12.5:37.5 0.56±0.07* Negative 
Control 
(DMEM)
0.97±0.07
25 0.49±.001* 75 0.56±.002 25:75 0.49±0.09*
50 0.43±0.04* 150 0.45±0.03* 50:150 0.41±0.05**
100 0.35±0.03* 300 0.39±0.01** 100:300 0.38±0.03***
150 0.33±0.02** 450 0.35±0.02*** 150:450 0.34±0.03***
200 0.29±0.06** 600 0.32±0.02*** 200:600 0.29±0.01***
cConcentration =µg/ml, bOD= Mean optical density of the cells against the control exposed to that concentration in terms of mean± 
standard deviation. Statistical significance was analyzed using the two-way ANOVA followed by Post Hoc Duncan, *P < 0.05, 
**P < 0.01, ***P < 0.001 vs positive control, * P<0.05, **P < 0.01, ***P < 0.001 vs positive control. 
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Damage index = No. Of cells in Class 1 + (2 × No. of the 
cells in Class 2) + (3× No. of cells in Class 3)         (2)
Mutagenicity (AMES assay)
Pre-incubation assay was utilized for mutagenicity 
evaluation of Carvedilol and Celecoxib. Mutagenic 
potential of carvedilol, celecoxib and combinations were 
evaluated on two Salmonella typhi tester strains TA100 
and TA98. Both tester strains TA 98 and TA 100 were 
inoculated in a fresh sterilized nutrient broth for 15-18 h 
prior to the assay performance. The Bacterial number was 
balanced at 0.5 mcfarland (mcf) by adjusting the optical 
density using spectrophotometer. Each drug dilution 
was exposed with 0.1 mL of bacterial suspension (2 x 
108 bacteria), incubated for 20 minutes and then spread 
over GM ager plates. Plates were then incubated for 48 
h at 37 ˚C. Likewise, the procedure was replicated with 
metabolic activation system (S9 mix) by adding 0.5 mL 
of the S9 fraction in each drug dilution. Finally, histidine 
independent revertant colonies were counted manually and 
results were calculated in term of mutagenic index by the 
following formula (Mortelmans, Zeiger, 2000)
Mutagenic Index 
Negative Control ×2 = Possible Mutagen, Negative 
Control × 3 = Significant Mutagen, Negative Control × 4 
and above = Highly Significant Mutagen
Statistical analysis
The results were analyzed by Statistical Package 
Of Social Sciences (SPSS for windows version 16, SPSS 
Inc., Chicago IL USA). The results were explained 
in terms of means ± SD. The results were considered 
significant if the (p<0.05), (p<0.01) and (p<0.001). 
Analysis of variance (TWO WAYANOVA) along with 
Post Hoc Duncan test was applied to the data to find 
out the relation between the DNA damage index, Cell 
survival percentage and the relationship between the 
means of mutagenic index and dose response among the 
treatments (Aghbali et al., 2014).
RESULTS
MTT assay
After incubating the cells for 48hrs with test 
samples, results were presented in form of cell survival 
percentage (CSP) (Figure 1). All three treatments 
significantly (P<0.05) inhibited the proliferation of Vero 
cell in a concentration-dependent manner. Recorded IC50 
for carvedilol and celecoxib were 20.4±0.2 µg/mL and 
84.7±0.3 µg/mL, respectively, whereas their combinations 
have shown increase pattern of cytotoxicity with a combine 
IC50 of 13.7:47.8 µg/mL. The effects of combinations were 
more cytotoxic as compared to individual drugs (Figure 1).
Comet assay
The genotoxic potentials of carvedilol, and celecoxib 
were evaluated on peripheral mononuclear cells and extent 
of the DNA damage was expressed in terms of percentage 
fragmentation of DNA (Table II). Carvedilol has exhibited 
FIGURE 1 - Concentration dependent response in cell survival percentage (CSP) of Vero cells (2 x 104 cells/0.1 mL/well) assessed 
by MTT assay after 48 hours of incubation with test chemicals, (A) comparison of CSP after carvedilol and combine concentration 
of carvedilol and celecoxib (B) comparison of CSP after celecoxib and combine concentration of carvedilol and celecoxib. The 
graph shows that anti-proliferative effect of combine concentration carvedilol:celecoxib) was significant at lower level as compare 
to both carvedilol and celecoxib alone. Each value represent of mean three replicates (n=3). The asterisks indicate significant 
difference at three levels (*p<0.05, **p<0.01, ***p<0.001) between cells cultured after 48 hours of treatments.
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maximum DNA damage at 200 µg/mL leading to Class 3 
tail formation (Figure 3). Moreover, at lowest tested 
concentration of Carvedilol (0.78 µg/mL), head to tail 
ratio was approximately 2:1 with 10% DNA fragmentation 
and class 1 damage (Figure 3). Whereas for celecoxib 
damage was only observed at concentrations ≥75 µg/mL 
with class 3 damage and 100% fragmentation (Figure 3, 
Table II). Furthermore, maximum tail length formation 
was observed with carvedilol and celecoixb combinations, 
where an average of class 3 damage with as average of 
30% fragmentation was recorded at concentration range of 
0.78:2.34 µg/mL to 200:600 µg/mL (Table II), suggesting 
that combination of carvedilol and celecoxib has exhibited 
synergetic genotoxic potential (Figure 3).
AMES assay
Mutagenic potential of Carvedilol, Celecoxib and 
combinations were evaluated on two Salmonella typhi 
tester strains TA100 and TA98. After incubating the 
mutant strains for 48hrs with the test concentrations, 
results were presented in terms of number of revertant 
colonies/plate and mutagenic index as shown in Table III. 
As expected, carvedilol and celecoxib failed to produce 
histidine independent revertant colonies in both TA98 
and TA 100. However, mild to moderate mutagenicity 
was observed when combination of Carvedilol and 
Celecoxib were incubated with mutant strain and 
metabolic activation system was added to mimic the in 
vivo condition. Upon addition of metabolic activation 
system histidine independent revertent colonies were 
observed at concentrations ≥3.12: 9.38 µg/plate, with 
mutagenic index of ≥2.0 (Table III). On the other hand, 
the combinations of both drugs were not mutagenic at 
therapeutic concentrations of 0.04 µg/mL and 1.14 µg/mL 
of carvedilol and celecoxib, respectively (Table III).
DISCUSSION 
The superior therapeutic efficacy of carvedilol in 
lowering blood pressure and of celecoxib on inflammatory 
pains motivated physician to prescribe this combination 
for multiple years and in some cases for entire life. The 
possible cytotoxic, genotoxic and mutagenic effect of 
combination of carvedilol and celecoxib were evaluated in 
this study using well-established MTT, Ames and SCGE 
in vitro assay. Carvedilol has shown promising results in 
several anti-proliferative studies. Proposed mechanisms 
includes (a) Ca2+ release from the endoplasmic reticulum 
which leads to apoptosis (Cheng et al., 2007) and (b) direct 
mitochondrial damage causing cells arrest at G0/G1 phase 
(Erguven et al., 2010). In this experiment, carvedilol has 
shown substantial cytotoxicity at concentrations above 
12.5 µg/mL, and IC50 20.4±0.22 µg/mL (Figure 1). The 
following concentrations of carvedilol; 25 µg/mL, 50 
µg/mL, 100 g/mL, 150 µg/mL and 200 µg/mL have 
statistically significant difference in CSP as compared to 
control (Figure 1), whereas celecoxib results suggested 
that concentrations >75 µg/mL are potential cytotoxic 
for given cell line with IC50 84.7±0.34 µg/mL (Table I). 
Literature suggests that its COX-2 growth-inhibitory and 
apoptosis-stimulatory potential is primarily responsible 
for its noticeable anti-proliferative activity (Zuo et al., 
2015). Furthermore, test concentrations of combinations 
produced synergistic cytotoxic potential and cell viability 
of Vero cell line plunged abruptly upon exposure. Seven 
combined concentrations (6.25:18.75 µg/mL, 12.5:37.5 
µg/mL, 25:75 µg/mL, 50:150 µg/mL, 100:300 µg/mL, 
FIGURE 2 - DNA damage index of carvedilol, celecoxib and their combination (carvedilol:celecoxib) in peripheral blood 
mononuclear cells (PBMCs) measured by Single Cell Gel Electrophoresis, (A) comparison of DNA damage index after carvedilol 
and combination (B) comparison of DNA damage index after celecoxib and combination. The graphs shows that the DNA damage 
induced after treatment with carvedilol and combine concentrations were significant. Nevertheless DNA damages induced by >75 
µg/mL of celecoxib were also genotoxic when used alone and combinations. Each Value represent of mean three replicates (n=3). 
The asterisk indicate significant difference at **p<0.01 between cells. 
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150:450 µg/mL, 200:600 µg/mL) showed statistically 
significant difference in CSP as compare to control 
cells (Table I) exhibiting an increase cytotoxicity of 
combination. Previously, both drugs have been analyzed 
in combination with known anticancer drugs. Carvedilol 
has shown greater cytotoxicity with imatinib against brain 
tumor (Erguven et al., 2010) and with doxorubicin against 
breast cancer (Jonsson et al., 1999). Data suggested that 
similar attribute has been associated with Celecoxib 
as well, combination of Cisplatin and Celecoxib has 
enhanced therapeutic response against chemotherapy 
resistant gastric cancer (Xu, Shen, Lv et al., 2016), with 
Imatinib, Celecoxib has shown superior efficacy against 
Chronic myelogenous leukemia (CML) by suppressing 
TABLE II - Percentage fragmentations of DNAs in the peripheral blood mononuclear cells (PBMCs) measured by single cell gel 
electrophoresis (comet assay) after 3 h incubation with various concentrations of Carvedilol, Celecoxib and their combination 
compared to respective controls. 
Treatment Concentration 
(μg/ml)
Mean DNA Head 
Length (µm)
Mean Tail length 
(µm)
%Fragmentation 
Carvedilol
200 1.97 ±0.65 8.46±2.54 100**
150 1.96±0.80 8.09±2.41 92**
100 2.15±0.16 7.36±2.10 92**
50 2.16±0.98 6.21±2.41 84**
25 2.20±0.55 5.00±1.95 76
12.6 2.41±0.31 4.68±2.56 68
6.25 3.51±0.40 3.418±1.48 60
3.125 3.57±1.48 2.59±0.57 52
1.56 3.76±1.91 2.09±1.59 48
0.78 3.99±1.06 2.33±1.18 10
Celecoxib
600 2.59 ±0.392 10.81±0.701 100**
450 2.66±0.410 10.07±0.805 100**
300 3.06±0.1903 7.03±2.134 100**
150 4.34±01.468 6.21±2.411 100**
75 2.20±0.559 4.36±0.662 92**
37.5 4.15±1.601 0.482±1.279 36
18.75 4.16±0.573 0.489±1.125 36
9.375 4.50±1.125 0±0.00 10
4.69 5.22±0.941 0±0.00 9
2.34 5.76±1.063 0±0.00 5
Carvedilol:Celecoxib 
200:600 1.68 ±0.81 9.46±1.49 100**
150:450 1.77±1.49 8.28±0.94 100**
100:300 2.01±0.53 7.70±0.66 100**
50:150 2.59±0.67 6.06±1.52 100**
25:75 3.21±0.68 4.92±1.58 92**
12.5:37.5 3.33±1.12 4.51±0.95 88**
6.25:18.75 3.42±0.63 4.07±1.12 76
3.125:9.375 4.50±1.12 3.78±1.31 64
1.56:4.69 5.22±0.94 3.27±1.12 56
0.78:2.34 5.76±1.06 3.11±0.56 36
Positive Control 20 % DMSO 0.78±0.011 13.3±0.333 78
Negative Control RPMI Medium 5.78±0.166 0.37±0.002 8
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FIGURE 3 - Representative comets with increasing concentrations of three treatment groups. [A] shows the comets protrude by 
carvedilol 200 µg/mL, 150 µg/mL, 0.72 µg/mL and negative control (Class 0 Damage) [B] Shows the comets protrude by celecoxib 
600 µg/mL, 450 µg/mL and 2.34 µg/mL and negative control [C] Shows the comets protrude by combine concentrations of 
carvedilol and celecoxib 200:600 µg/mL, 150:450 µg/mL, 0.72:2.34 µg/mL and negative control (Class 0 Damage) respectively.
TABLE 3. Shows the mutagenic potential in terms of mean number of revertant colonies/plate, standard deviation (SD) and 
mutagenic index (M.I) recorded against salmonella typhi TA-98 and TA-100, in the presence (+S9) and absence (-S9) of metabolic 
activation system.
Treatment µg/Plate 
Mean Number of revertant (M ± SD)/plate and MI in parenthesis
TA 98 TA 100
-S9 +S9 -S9 +S9
Carvedilol
0.78 54±2 (0.83) 79±3 (0.89)  89±3 (0.90) 103±5 (0.88)
1.56 63±4 (0.96) 106±6 (1.21)  99±4 (1.10) 110±6 (0.94)
3.12 69±7 (1.06) 124±3 (1.41) 104±3 (1.06) 131±4 (1.11)
6.26 73±3 (1.12) 134±7 (1.53) 130±5 (1.33) 177±8 (1.50)
12.5 88±5 (1.36) 149±4 (1.70) 154±6 (1.57) 6221±3 (1.88)
Celecoxib
2.34 52±3 (0.81) 81±3 (0.92) 81±2 (0.82) 98±5 (0.83)
4.69 60±2 (0.91) 88±1 (1) 93±3 (0.94) 114±4 (0.96)
9.37 63±6 (0.96) 95±7 (1.07) 101±7 (1.03) 141±8 (1.19)
18.75 79±1 (1.21) 144±9 (1.64) 156±6 (1.59) 198±5 (1.67)
37.5 93±8 (1.43) 156±5 (1.77) 169±8 (1.72) 216±11(1.83)
Carvedilol:Celecoxib
0.78:2.34 88±2 (1.35) 146±3 (1.66) 155±5 (1.58) 205±7 (1.74)
1.56:4.68 100±4 (1.55) 157±4 (1.79) 175±4 (1.78) 219±4 (1.86)
3.12.9.73 115±7 (1.77) 172±8 (1.96)* 189±8 (1.92)* 244±8 (2.07)*
6.25:18.75 145±4 (2.24)** 218±4 (2.48)** 213±5 (2.17)* 333±6 (2.82)*
12.5:37.5 166±7 (2.55)** 248±6 (2.82)** 268±6 (2.73)** 353±9 (2.99)***
Positive Control 540±65b 1220±70c 756±53b 1540±88c
Negative Control 65±4a 88±5a 98±4a 118±6a
M±SD= mean and standard deviation; MI= mutagenic index; aNegative control: Dimethylsulfoxide (50µl/plate);bPositive control 
sodium Azide with out S9 (5µg/plate); c2-amino Anthracycline (800µl/plate) with S9. Control-×2*, Control-×3**, Control-×4 and 
above ***. *=Possible Mutagen;**=Significant Mutagen;***Highly Significant Mutagen
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the autophagy and increasing cytotoxicity. Celecoxib with 
radiotherapy has shown promising results by G2-M cell 
phase arrest and enhancement of cell apoptosis (Zhang et 
al., 2014). Hence, molecular target therapy can be used 
to target advanced malignancies of certain types and 
carvedilol in combination with celecoxib can be an option 
in the treatment or prevention of neoplasm particularly in 
hypertensive patients. 
The genotoxicity evaluation of carvedilol 
and celecoxib were assessed using single cell gel 
electrophoresis (Comet assay) on peripheral blood 
mononuclear cells. There is a paucity of information 
on the toxicity of carvedilol in literature. However, 
few shreds of evidence have been found in literature to 
support our data (Table II). Aruna and Krishnamurthy 
(1986) Suggested induction of a significant increase in 
the frequency of micronuclei observed in erythrocyte 
at higher dose levels of propanolol. Many years later 
Sedigh-Ardekani, Saadat and Saadat (2013) shared the 
same concern about the non-selective beta blockers. Our 
data indicates that significant tail formation was observed 
in all the test concentrations range of 0.78 µg/mL-200 µg/
mL of Carvedilol, when compared with negative control 
(Figure 3). On the contrary, DNA damage was only 
observed at concentrations ≥75µg/mL for celecoxib. But 
at concentrations <75 µg/mL the tail formation decreased 
momentously, showing class 0, insignificant damage 
(Figure 3). Moreover, the combination of carvedilol and 
celecoxib were subjected to SCGE for evaluation of their 
genotoxicity potentials. Out of all the tested concentrations 
four have shown significant (p<0.05) DNA damage 
(Table II). The reason of these concentrations for being 
conspicuous is because reported genotoxic concentrations 
fall under threshold value of combined IC50 (13.4:47.9 µg/
mL). Henceforth, these concentration may bring about 
DNA damage yet not kill them. The consolidated impact of 
DNA damage, DNA repair defects, and an inability to stop 
or slow down the cell cycle (Lord, Ashworth, 2012). Our 
results also suggest a synergetic genotoxicity when our 
test drugs were used in combinations (Figure 3). Previous 
studies carried out on effects of drugs in combinations 
also support our data (Carter et al., 2007, Guimaraes et 
al., 2003). 
DNA damage and chromosomal aberration can be 
a major cause for the development and progression of 
cancer (Hagmar et al., 2004). To validate this claim we 
tested carvedilol and celecoxib against Salmonella typhi 
TA98 and TA 100 for the evaluation of their mutagenicity 
potential alone and in combinations (Table III). Individual 
test concentrations of carvedilol and celecoxib did not 
show any signs of mutation against either strains of 
Salmonella typhi. Nevertheless, upon addition of metabolic 
activation system significant rise in mutagenic index was 
observed. The concentrations, which were mutagenic for 
TA-100, were almost equally mutagenic for TA-98. The 
three out of five concentrations used in this project have 
exhibited mild to moderate mutagenic potential (Table 
III). Carvedilol and Celecoxib combinations have shown 
significant (P<0.05) mutagenic potential, against negative 
control at following concentrations 3.12.9.73 µg/mL, 
6.25:18.75 µg/mL and 12.5:37.5 µg/mL. Several reports 
regarding the mutagenic synergism by combination of 
drugs are in support of our data. (Mansky, 2003, Torres 
et al., 2007). For instance, in recent work of Fatima et al. 
(2013) emphasized that all anti-TB drugs, specifically in 
combination, possess substantial cytotoxic and mutagenic 
potential making TB patient more susceptible to cytotoxic 
and mutagenic effects of anti-TB drugs, which could 
produce further health complications. These collective 
data suggest genomic instability is one of the most 
pervasive characteristics of tumor cells and is probably 
the combined effect of DNA damage, tumor-specific DNA 
repair defects, and a failure to stop or stall the cell cycle 
before the damaged DNA is passed on to daughter cells, 
hence our drug combinations may cause host cell DNA 
damage and mutations, and impose a cancer risk. 
CONCLUSION 
These collective data suggest Genomic instability 
is one of the most pervasive characteristics of tumor cells 
and is probably the combined effect of DNA damage, 
tumor-specific DNA repair defects, and a failure to 
stop or stall the cell cycle before the damaged DNA is 
passed on to daughter cells, hence our drug combinations 
may cause host cell DNA damage and mutations, and 
impose a cancer risk. It was concluded from the results 
that combination of Carvedilol and Celecoxib can be 
mutagenic, genotoxic and cytotoxic. Professional medical 
advice should be recommended before taking these 
medications in combination. These drugs should be taken 
at low concentrations for a shortest period of time. 
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